KNTE Overview

Kinnate Biopharma Inc. is a clinical-stage precision oncology company. It is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. It is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).

Wall Street analysts forecast KNTE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNTE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kinnate Biopharma Inc revenue for the last quarter amounts to NaN USD, decreased % YoY.

Kinnate Biopharma Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Kinnate Biopharma Inc (KNTE) has 27 emplpoyees as of February 10 2026.

Today KNTE has the market capitalization of 125.15M USD.